| Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. | |
| | |
MedLine Citation:
|
PMID: 19325013 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Buprenorphine (BUP) is under investigation as a medication therapy for opioid-dependent pregnant women. We investigated BUP and metabolite disposition in urine from women maintained on BUP during the second and third trimesters of pregnancy and postpartum. METHODS: We measured BUP, norbuprenorphine (NBUP), buprenorphine glucuronide (BUP-Gluc), and NBUP-Gluc concentrations in 515 urine specimens collected thrice weekly from 9 women during pregnancy and postpartum. Specimens were analyzed using a fully validated liquid chromatography-mass spectrometry method with limits of quantification of 5 microg/L for BUP and BUP-Gluc and 25 microg/L for NBUP and its conjugated metabolite. We examined ratios of metabolites across trimesters and postpartum to identify possible changes in metabolism during pregnancy. RESULTS: NBUP-Gluc was the primary metabolite identified in urine and exceeded BUP-Gluc concentrations in 99% of specimens. Whereas BUP-Gluc was identified in more specimens than NBUP, NBUP exceeded BUP-Gluc concentrations in 77.9% of specimens that contained both analytes. Among all participants, the mean BUP-Gluc:NBUP-Gluc ratio was significantly higher in the second trimester compared to the third trimester, and there were significant intrasubject differences between trimesters in 71% of participants. In 3 women, the percent daily dose excreted was higher during pregnancy than postpregnancy, consistent with other data indicating increased renal elimination of drugs during pregnancy. CONCLUSIONS: These data are the first to evaluate urinary disposition of BUP and metabolites in a cohort of pregnant women. Variable BUP excretion during pregnancy may indicate metabolic changes requiring dose adjustment during later stages of gestation. |
| | |
Authors:
|
Sherri L Kacinko; Hendree E Jones; Rolley E Johnson; Robin E Choo; Marta Concheiro-Guisan; Marilyn A Huestis |
Related Documents
:
|
8230313 - Classification of adverse reproductive effects can be improved by measurements of multi... 6933363 - An evaluation of the performance of laboratories in the assays of oestriol and creatini... 11251483 - Is it necessary to suture all lacerations after a vaginal delivery? |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural Date: 2009-03-26 |
Journal Detail:
|
Title: Clinical chemistry Volume: 55 ISSN: 1530-8561 ISO Abbreviation: Clin. Chem. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-05-29 Completed Date: 2009-06-19 Revised Date: 2011-09-13 |
Medline Journal Info:
|
Nlm Unique ID: 9421549 Medline TA: Clin Chem Country: United States |
Other Details:
|
Languages: eng Pagination: 1177-87 Citation Subset: IM |
Affiliation:
|
Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Buprenorphine / therapeutic use*, urine Double-Blind Method Female Humans Narcotic Antagonists / therapeutic use*, urine Pregnancy Pregnancy Complications / drug therapy* Pregnancy Trimester, Second Pregnancy Trimester, Third |
| Grant Support | |
ID/Acronym/Agency:
|
ZIA DA000433-11/DA/NIDA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Narcotic Antagonists; 52485-79-7/Buprenorphine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic A...
Next Document: Intravenous administration of low molecular weight and unfractionated heparin elicits a rapid increa...